Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

The proteasome inhibitor bortezomib (Velcade) is currently approved as second-line treatment of multiple myeloma (MM). MM-related bone disease is one of the most debilitating complications of MM. Besides supportive care with biphosphonates, which have proven efficacy in reducing and delaying skeletal-related events, there is no specific treatment of lytic bone lesions. The present study investigated the effect of bortezomib alone or in combination with a hydroxamate-based histone deacetylase inhibitor, JNJ-26481585 on tumor burden, and MM bone disease in the 5T2MM model. Injection of 5T2MM cells into C57Bl/KaLwRij mice resulted in MM bone disease, characterized by an increase in the percentage osteoclasts, a decrease in osteoblasts, trabecular bone volume, trabecular number, and the development of bone lesions. Treatment of 5T2MM-bearing mice with bortezomib significantly reduced tumor burden, angiogenesis, and MM bone disease. More importantly, the combination of bortezomib with JNJ-26481585 resulted in a more pronounced reduction of osteoclasts and increase of osteoblasts, trabecular bone volume, and trabecular number compared with bortezomib as single agent. These data suggest that bortezomib has bone remodeling properties that can be improved in combination with low dose JNJ-26481585. The study indicates that this combination therapy could be a useful strategy for the treatment of MM patients, especially in those patients with skeletal complications.

[1]  M. Mapara,et al.  The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage , 2007, British journal of haematology.

[2]  K. Anderson,et al.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. , 2006, Blood.

[3]  S. Hung,et al.  Sodium butyrate activates ERK to regulate differentiation of mesenchymal stem cells. , 2007, Biochemical and biophysical research communications.

[4]  D. Ribatti,et al.  Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.

[5]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  K. Vanderkerken,et al.  The 5TMM series: a useful in vivo mouse model of human multiple myeloma. , 2000, The hematology journal : the official journal of the European Haematology Association.

[7]  M. Dimopoulos,et al.  Myeloma bone disease and proteasome inhibition therapies. , 2007, Blood.

[8]  P. Croucher,et al.  The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models , 2009, Leukemia.

[9]  O. Sezer,et al.  Bortezomib inhibits human osteoclastogenesis , 2007, Leukemia.

[10]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[11]  G. Mundy,et al.  Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease , 2007, British journal of haematology.

[12]  M. Mohty,et al.  VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial. , 2007 .

[13]  J. Fraczek,et al.  Screening of Trichostatin Analogues Based on Cellular Potency in the Murine Multiple Myeloma 5T33MM Model , 2008 .

[14]  L. Devy,et al.  Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo , 2002, British Journal of Cancer.

[15]  N. Munshi,et al.  The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. , 2006, European journal of cancer.

[16]  P. Croucher,et al.  The 5T2MM murine model of multiple myeloma: maintenance and analysis. , 2005, Methods in molecular medicine.

[17]  N. Munshi,et al.  New drugs for myeloma. , 2007, The oncologist.

[18]  M. Zangari,et al.  The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo , 2009, American journal of hematology.

[19]  H. Ryoo,et al.  Trichostatin A-mediated upregulation of p21WAF1 contributes to osteoclast apoptosis , 2007, Experimental & Molecular Medicine.

[20]  G. Stein,et al.  Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. , 2008, The Journal of clinical investigation.